Литература
1. Безруков А.В., Бухаров С.Г., Кузнецов Д.А. и др. Цитологический скрининг на РШМ: какую технологию выбрать? // ГК "ЭМКО", ООО "МЛТ", III Конгресс лабораторной медицины России. М., 11-13 октября. 2017. 12 с.
2. Минкина Г.Н. Цитологический скрининг рака шейки матки: от традиционного ПАП-теста к компьютерным технологиям // Акуш., гин. и репрод. 2017. Т. 11, № 1. С. 56-63. doi: 10.17749/2313-7347.2017.11.1.056-063.
3. ВОЗ. Вирус папилломы человека (ВПЧ) и рак шейки матки: информационный бюллетень [Электронный ресурс]. Февраль. 2018 г. URL: http:// www.who.int/ru/news-room/fact-sheets/detaiL/human-papiLLomavirus-(hpv)-and-cervicaL-cancer.
4. American CoLLege of Pediatricians. New concerns about the human papiLLomavirus vaccine. 2016. URL: http://www.acpeds.org/the-coLLege-speaks/position-statements/heaLth-issues/new-concerns-about-the-human-papiLLomavirus-vaccine.
5. BhatLaa N., Neneb B.M., Joshic S. et aL. Are two doses of human papiLLomavirus vaccine sufficient for girls aged 15-18 years? ResuLts from a cohort study in India // PapiLLomavirus Res. 2018. VoL. 5. P. 163-171.
6. Bogani G., Taverna F., Lombardo C. et aL. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytoLogy // Int. J. GynaecoL. Obstet. 2017. VoL. 138. P. 62-68.
7. Bogani G., Lousso D., RaspagLiesi F. Safety and effectiveness of human papiLLomavirus (HPV) vaccination: NCI of MiLan position statement // Vaccine. 2017. VoL. 35 , N 39. P. 5227. doi: 10.1016/j.vaccine.2017.06.068.
8. Bogani G. The roLe of human papiLLomavirus vaccines in cervicaL cancer: prevention and treatment // Crit. Rev. OncoL. HematoL. 2018. VoL. 122. P. 92-97.
9. Brinth L.S., Pors K., TheibeL A.C. Orthostatic intoLerance and posturaL tachycardia syndrome as suspected adverse effects of vaccination against human papiLLoma virus // Vaccine. 2015. VoL. 33, N 22. P. 26022605. doi: 10.1016/j.vaccine.2015.03.098.
10. Brotherton J.M.L., BLoem P.N. PopuLation-based HPV vaccination programs are safe and effective: 2017 update and the impetus for achieving better gLobaL coverage // Best Pract. Res. CLin. Obstet. GynaecoL. 2018. VoL. 47. P. 42-58.
11. Campos N.G., Lince-Deroche N., Chibwesha C.J. et aL Cost-effectiveness of cervical cancer screening in women living with HIV in South Africa: a mathematical modeling study // J. Acquir. Immune Defic. Syndr. 2018 June 15. doi: 10.1097/QAI.0000000000001778.
12. Castle P.E., Kinney W.K., Cheung L.C. Why does cervical cancer occur in a state-of-the-art screening program? // Gynecol. Oncol. 2017. VoL 146, N 3. P. 546-553. doi: 10.1016/j.ygyno.2017.06.003.
13. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccine safety [Electronic resource]. CDC, 2017. URL: www.cdc. gov/ vaccinesafety/vaccines/hpv-vaccine.htmi.
14. European Medicines Agency (EMA). Human Papillomavirus vaccines [Electronic resource]. EMA // Science Medicines Health. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/refer-rals/Human_papiltomavirus_vaccines/human_referraLprac_000053.jsp& mid=WC0b01ac05805c516f.
15. European Medicines Agency (EMA). Cervarix: human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) [Electronic source]. EMA // Summary for the Public. URL: http://www.ema. europa.eu/docs/en_GB/document_iibrary/EPAR_-_Summary_for_the_ public/human/000721/WC500024634.pdf).
16. Food and Drug Administration (FDA). Vaccines, Blood and Biologics. FDA, 2017. URL: https://www.fda.gov/BioiogicsBioodVaccines/Vaccines/ApprovedProducts.
17. Gamaoun R. Awareness and knowledge about cervical cancer prevention methods among Tunisian women // J. Prev. Med. Hyg. 2018. VoL 59, N 1. P. 30-35. doi: 10.15167/2421-4248/jpmh2018.59.1.709.
18. Ge Y., Christensen P., Luna E. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer // Cancer Cytopathoi. 2017. Voi. 125, N 8. P. 652-657.
19. Goodman S., Mody R.R., Coffey D. et al. Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: contributing factors and role of human papillomavirus genotyping // Diagn. Cyto-pathol. 2018. Vol. 46, N 3. P. 239-243. doi: org/10.1002/dc.23874.
20. Harper D.M., DeMars L.R. HPV vaccines - a review of the first decade // Gynecol. Oncol. 2017. Vol. 146. P. 196-204.
21. HPV Information Centre. Human papillomavirus and related diseases report [Electronic resource]. URL: http://www.hpvcentre.net/statis-tics/reports/XWX.pdf.
22. Huh W.K., Joura E.A., Giuliano A.R. et al. Final efficacy, immunoge-nicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial // Lancet. 2017. Vol. 390. P. 2143-2159. doi: 10.1016/S0140-6736(17)31821-4.
23. Huy N.V.Q., Le Tam M., Tram N.V.Q. The value of visual inspection with acetic acid and Pap smear in cervical cancer screening program in low resource settings - a population-based study // Gynecol. Oncol. Rep. 2018. Vol. 24. P. 18-20.
24. Joura E.A., Giuliano A.R., Iversen O.E. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women // N. Engl. J. Med. 2015. Vol. 372. P. 711-723.
25. Kamineni V., Nair P., Deshpande A. Can LBC completely replace conventional Pap smear in developing countries // J. Obstet. Gynecol. India. 2018 May 18. P. 1-8.
26. Koliopoulos G., Nyaga V.N., Santesso N. Cytology versus HPV testing for cervical cancer screening in the general population // Cochrane Database Syst. Rev. 2017. Vol. 8. doi: 10.1002/14651858.CD008587.pub2.
27. Kyrgiou M., Athanasiou A., Kalliala I.E.I. et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease // Cochrane Database Syst. Rev. 2017. Vol. 11. CD012847.
28. Leite K.R.M., Silva T., Naum B. Validation of a new low-cost, methanol-based fixative for cervical cytology and human papillomavirus detection // Acta Cytol. 2018 June 18. P. 1-4. doi: 10.1159/000489873.
29. Markowitz L.E., Liu G., Hariri S. et al. Prevalence of HPV after introduction of the vaccination program in the United States // Pediatrics. 2016. Vol. 137, N 3. Article ID e20151968. doi: 10.1542/peds.2015-1968.
30. Martinez-Lavin M. Hypothesis: human papillomavirus vaccination syndrome small fiber neuropathy and dysautonomia could be its underlying pathogenesis // Clin. Rheumatol. 2015. Vol. 34, N 7. P. 1165-1169. doi: 10.1007/s10067-015-2969-z.
31. Moreira E.D., Block S.L., Ferris D. et al. Safety profile of the 9-va-lent HPV vaccine: a combined analysis of 7 phase III clinical trials // Pediatrics. 2016. Vol. 138, N 2. Article ID e20154387.
32. National Centre for Immunization Research and Surveillance. Human papillomavirus (HPV) vaccines for Australians: information for immunisation providers. URL: http://www.ncirs.edu.au/assets/provider_re-sources/fact-sheets/human-papillomavirus-hpv-fact-sheet.pdf.
33. Nayani Z.S., Hendre P.C. Comparison and correlation of Pap smear with colposcopy and histopathology in evaluation of cervix // J. Evol. Med. Dental Sci. 2015. Vol. 4, N 53. P. 9236-9247. doi: 10.14260/jemds/ 2015/1341.
34. Nordic Cochrane Centre. Complaint to the European ombudsman over maladministration at the European Medicines Agency (EMA) in relation to the safety of the HPV vaccines [Electronic resource]. 10 October 2016. URL: http://nordic.cochrane.org/sites/nordic.co-chrane.org/files/public/uploads/complaint-to-ombudsman-over-ema_ 101016.pdf.
35. Padmini C.P., Indira N., Chaitra R. et al. Cytological and col-poscopic evaluation of unhealthy cervix // J. Evid. Based Med. Healthc. 2015. Vol. 2. P. 6920-6927. doi: 10.18410/jebmh/2015/925.
36. Paluszkiewicz A., Pruski D., Iwaniec K. et al. Comparison of the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low-grade and high-grade squamous intraepithelial lesions across different age groups // Ginekol. Pol. 2017. Vol. 88, N 3. P. 141-146. doi: 10.5603/GP.a2017.0027.
37. Phaliwong P., Pariyawateekul P., Khuakoonratt N. Cervical cancer detection between conventional and liquid based cervical cytology: a 6-year experience in Northern Bangkok Thailand // Asian Pac. J. Cancer Prev. 2018. Vol. 19, N 5. P. 1331-1336.
38. Phillips A., Patel C., Pillsbury A. et al. Safety of human papillomavirus vaccines: an updated review // Drug Saf. 2017. Vol. 41, N 4. P. 329-346. doi: 10.1007/s40264-017-0625-z.
39. Pirtea L., Margan M., Moleriu L. et al. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women under 30 years old // Bosn. J. Basic Med. Sci. 2018 June 20. doi: 10.17305/ bjbms.2018.3560.
40. Randomized Controlled Trials of Human Papillomavirus Vaccines: Systematic Reviews Prepared by Cochrane Response. London, UK, 2016. URL: http://www.who.int/immunization/sage/meetings/2016/october/04_Clinical_trials_of_HPV_vaccines.pdf.
41. Russian National Immunisation Office. HPV Vaccine [Electronic resource]. URL: https://www.hse.ie/eng/health/immunisation/infomate-rials/leafletstranslations/russianhpv.pdf.
42. Saraiya M., Unger E.R., Thompson T.D. et al. US assessment of HPV types in cancer: implications for current and 9-valent HPV vaccines // J. Natl Cancer Inst. 2015. Vol. 107, N 6. Article ID djv086. doi: 10.1093/ jnci/djv086.
43. Schiffman M., Castle P.E. The promise of global, cervical cancer prevention // N. Engl. J. Med. 2005. Vol. 353. P. 2101-2104. doi: 10.1056/ NEJMp058171.
44. Schisler T.M., Bhavsar A.K., Whitcomb B.P. et al. Human papillomavirus genotypes in Pacific Islander cervical cancer patients // Gynecol. Oncol. Rep. 2018. Vol. 24. P. 83-86.
45. Singh V.B., Gupta N., Nijhawan R. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears: experience from the first 1000 split samples // Indian J. Pathol. Microbiol. 2017. Vol. 58, N 1. P. 17-21.
46. Sumithra S., Manonmani R. An evaluation of Pap smear, colposcopy, HPV DNA testing in screening of cervical cancer // IOSR J. Dent. Med. Sci. (IOSR-JDMS). 2016. Vol. 15, N 9. P. 41-48.
47. Verma A., Verma S., Vashist S. et al. A study on cervical cancer screening in symptomatic women using Pap smear in a tertiary care hospital in rural area of Himachal Pradesh, India // Middle East Fertil. Soc. J. 2017. Vol. 22. P. 39-42.
48. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety. 7-8 June 2017 // Wkly Epidemiol. Rec. 2017. Vol. 92. P. 393-402.
49. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017 - recommendations // Vaccine. 2017. Vol. 35, N 43. P. 5753-5755. doi: org/10.1016/j.vaccine.2017.
50. World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva : WHO, 2013. 60 p.
References
1. Bezrukov A.V., Bukharov S.G., Kuznetsov D.A., et al. Cytological screening for cervical cancer: what technology to choose? In: III Congress of Laboratory Medicine in Russia. Moscow, October 11-13, 2017: 12 p. (in Russian)
2. Minkina G.N. Cytological screening of the cervical cancer: from the traditional PAP-test to computer technologies. Akusherstvo, ginekologiya, reproduktsiya. [Obstetrics, Gynecology, Reproduction]. 2017; 11 (1): 56-63. doi: 10.17749/2313-7347.2017.11.1.056-063. (in Russian)
3. WHO. Human papilloma virus (HPV) and cervical cancer: newsletter [Electronic resource]. February. 2018. URL: http://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. (in Russian)
4. American College of Pediatricians. New concerns about the human papillomavirus vaccine. 2016. URL: http://www.acpeds.org/the-college-speaks/position-statements/health-issues/new-concerns-about-the-human-papillomavirus-vaccine.
5. Bhatlaa N., Neneb B.M., Joshic S., et al. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. Papillomavirus Res. 2018; 5: 163-71.
6. Bogani G., Taverna F., Lombardo C., et al. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology. Int J Gynaecol Obstet. 2017; 138: 62-8.
7. Bogani G., Lousso D., Raspagliesi F. Safety and effectiveness ofhuman papillomavirus (HPV) vaccination: NCI of Milan position statement. Vaccine. 2017; 35 (39): 5227. doi: 10.1016/j.vaccine.2017.06.068.
8. Bogani G. The role of human papillomavirus vaccines in cervical cancer: prevention and treatment. Crit Rev Oncol Hematol. 2018; 122: 92-7.
9. Brinth L.S., Pors K., Theibel A.C. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015; 33 (22): 2602-5. doi: 10.1016/j.vaccine.2015.03.098.
10. Brotherton J.M.L., Bloem P.N. Population-based HPV vaccination programs are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 42-58.
11. Campos N.G., Lince-Deroche N., Chibwesha C.J., et al. Cost-effectiveness of cervical cancer screening in women living with HIV in South Africa: a mathematical modeling study. J Acquir Immune Defic Syndr. 2018 June 15. doi: 10.1097/QAI.0000000000001778.
12. Castle P.E., Kinney W.K., Cheung L.C. Why does cervical cancer occur in a state-of-the-art screening program? Gynecol. Oncol. 2017; 146 (3): 546-53. doi: 10.1016/j.ygyno.2017.06.003.
13. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccine safety [Electronic resource]. CDC, 2017. URL: www. cdc.gov/ vaccinesafety/vaccines/hpv-vaccine.html.
14. European Medicines Agency (EMA). Human Papillomavirus vaccines [Electronic resource]. EMA. In: Science Medicines Health. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Human_papillomavirus_vaccines/ human_referral_ prac_000053.jsp& mid=WC0b01ac05805c516f.
15. European Medicines Agency (EMA). Cervarix: human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) [Electronic source]. EMA. In: Summary for the Public. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf).
16. Food and Drug Administration (FDA). Vaccines, Blood and Biologics. FDA, 2017. URL: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts.
17. Gamaoun R. Awareness and knowledge about cervical cancer prevention methods among Tunisian women. J Prev Med Hyg. 2018; 59 (1): 30-5. doi: 10.15167/2421-4248/jpmh2018.59.1.709.
18. Ge Y., Christensen P., Luna E. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer. Cancer Cytopathol. 2017; 125 (8): 652-7.
19. Goodman S., Mody R.R., Coffey D., et al. Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: contributing factors and role of human papillomavirus genotyping. Diagn Cytopathol. 2018; 46 (3): 239-43. doi: org/10.1002/dc.23874.
20. Harper D.M., DeMars L.R. HPV vaccines - a review of the first decade. Gynecol. Oncol. 2017; 146: 196-204.
21. HPV Information Centre. Human papillomavirus and related diseases report [Electronic resource]. URL: http://www.hpvcentre.net/statistics/reports/XWX.pdf.
22. Huh W.K., Joura E.A., Giuliano A.R., et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, doubleblind trial. Lancet. 2017; 390: 2143-59. doi: 10.1016/S0140-6736(17) 31821-4.
23. Huy N.V.Q., Le Tam M., Tram N.V.Q. The value of visual inspection with acetic acid and Pap smear in cervical cancer screening program in low resource settings - a population-based study. Gynecol Oncol Rep. 2018; 24: 18-20.
24. Joura E.A., Giuliano A.R., Iversen O.E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372: 711-23.
25. Kamineni V., Nair P., Deshpande A. Can LBC completely replace conventional Pap smear in developing countries. J Obstet Gynecol India. 2018 May 18. P. 1-8.
26. Koliopoulos G., Nyaga V.N., Santesso N. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017; 8. doi: 10.1002/14651858.CD008587.pub2.
27. Kyrgiou M., Athanasiou A., Kalliala I.E.I., et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017; 11. CD012847.
28. Leite K.R.M., Silva T., Naum B. Validation of a new low-cost, methanol-based fixative for cervical cytology and human papillomavirus detection. Acta Cytol. 2018 June 18: 1-4. doi: 10.1159/000489873.
29. Markowitz L.E., Liu G., Hariri S., et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016; 137 (3) e20151968. doi: 10.1542/peds.2015-1968.
30. Martinez-Lavin M. Hypothesis: human papillomavirus vaccination syndrome small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol. 2015; 34 (7): 1165-9. doi: 10.1007/ s10067-015-2969-z.
31. Moreira E.D., Block S.L., Ferris D., et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016; 138 (2): e20154387.
32. National Centre for Immunization Research and Surveillance. Human papillomavirus (HPV) vaccines for Australians: information for immunisation providers. URL: http://www.ncirs.edu.au/assets/provider_ resources/fact-sheets/human-papillomavirus-hpv-fact-sheet.pdf.
33. Nayani Z.S., Hendre P.C. Comparison and correlation of Pap smear with colposcopy and histopathology in evaluation of cervix. J Evol Med Dent. Sci. 2015; 4 (53): 9236-47. doi: 10.14260/jemds/2015/ 1341.
34. Nordic Cochrane Centre. Complaint to the European ombudsman over maladministration at the European Medicines Agency (EMA) in relation to the safety of the HPV vaccines [Electronic resource]. 10 October 2016. URL: http://nordic.cochrane.org/sites/nordic. cochrane.org/files/public/uploads/complaint-to-ombudsman-over-ema_ 101016.pdf.
35. Padmini C.P., Indira N., Chaitra R., et al. Cytological and colposcopic evaluation of unhealthy cervix. J Evid Based Med Healthc. 2015; 2: 6920-7. doi: 10.18410/jebmh/2015/925.
36. Paluszkiewicz A., Pruski D., Iwaniec K., et al. Comparison of the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low-grade and high-grade squamous intraepithelial lesions across different age groups. Ginekol. Pol. 2017; 88 (3): 141-6. doi: 10.5603/GP.a2017.0027.
37. Phaliwong P., Pariyawateekul P., Khuakoonratt N. Cervical cancer detection between conventional and liquid based cervical cytology: a 6-year experience in Northern Bangkok Thailand. Asian Pac J Cancer Prev. 2018; 19 (5): 1331-6.
38. Phillips A., Patel C., Pillsbury A., et al. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2017; 41 (4): 32946. doi: 10.1007/s40264-017-0625-z.
39. Pirtea L., Margan M., Moleriu L., et al. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women under 30 years old. Bosn J Basic Med Sci. 2018 June 20. doi: 10.17305/ bjbms.2018.3560.
40. Randomized Controlled Trials of Human Papillomavirus Vaccines: Systematic Reviews Prepared by Cochrane Response. London, UK, 2016. URL: http://www.who.int/immunization/sage/meetings/2016/october/04_ Clinical_trials_of_HPV_vaccines.pdf.
41. Russian National Immunisation Office. HPV Vaccine [Electronic resource]. URL: https://www.hse.ie/eng/health/immunisation/infomaterials/leafletstranslations/russianhpv.pdf.
42. Saraiya M., Unger E.R., Thompson T.D., et al. US assessment of HPV types in cancer: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107 (6): djv086. doi: 10.1093/jnci/djv086.
43. Schiffman M., Castle P.E. The promise of global cervical cancer prevention. N Engl J Med. 2005; 353: 2101-4. doi: 10.1056/NEJMp058171.
44. Schisler T.M., Bhavsar A.K., Whitcomb B.P., et al. Human papillomavirus genotypes in Pacific Islander cervical cancer patients. Gynecol Oncol Rep. 2018; 24: 83-6.
45. Singh V.B., Gupta N., Nijhawan R. Liquid-based cytology versus conventional cytology for evaluation of cervical Pap smears: experience from the first 1000 split samples. Indian J Pathol Microbiol. 2017; 58 (1): 17-21.
46. Sumithra S., Manonmani R. An evaluation of Pap smear, colposcopy, HPV DNA testing in screening of cervical cancer. IOSR J Dent Med Sci (IOSR-JDMS). 2016; 15 (9): 41-8.
47. Verma A., Verma S., Vashist S., et al. A study on cervical cancer screening in symptomatic women using Pap smear in a tertiary care hospital in rural area of Himachal Pradesh, India. Middle East Fertil Soc J. 2017; 22: 39-42.
48. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety. 7-8 June 2017. Wkly Epidemiol Rec. 2017; 92: 393-402.
49. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017 - recommendations. Vaccine. 2017; 35 (43): 5753-5. doi: org/10.1016/j.vaccine.2017.
50. World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva : WHO, 2013: 60 p.